Abstract
In an attempt to understand the nature of the interactions between D1 and D2 dopamine subsystems as well as between dopamine and acetylcholine, catalepsy was assessed in rats following various drug treatments. The D1-specific antagonist SCH23390 (0.1 mg/kg) produced prompt, potent and brief (<90 min) catalepsy with an ED50 of 0.105 mg (0.3 μmol)/kg. Conversely, fluphenazine (0.1 mg/kg), spiroperidol (0.1 mg/kg), and haloperidol (0.2 mg/kg) all had comparably potent but more slowly rising and prolonged (>240 min) effects. The action of SCH23390 was synergistic with spiroperidol, inhibited by apomorphine or atropine, unaffected by mecamylamine, and markedly potentiated by pilocarpine. However, pilocarpine was unable to significantly potentiate the action of fluphenazine or spiroperidol. It is inferred that SCH23390 differs from the classical neuroleptics in its mechanism of cataleptogenicity, that there is a cholinergic link with the D1 dopamine system, and further, that there may be a difference in the nature or impact of the cholinergic interaction with the D1 and D2 dopamine systems.
Similar content being viewed by others
References
Borison RL, Diamond BI (1980) Anticholinergics promote neuroleptic-induced tardive dyskinesia. Adv Biochem Psychopharmacol 24:359–361
Brown JH, Brown SL (1984) Agonists differentiate muscarinic receptors that inhibit cyclic AMP formation from those that stimulate phosphoinositide metabolism. J Biol Chem 259:3777–3781
Carey RJ, De Veaugh-Geiss J (1982) Chronic benztropine and haloperidol administration induce behaviorally equivalent pharmacological hypersensitivities separately but not in combination. Psychopharmacology 76:341–345
Chang WH, Chen TY, Yeh EK (1987) Time-response curves of homovanillic acid in caudate and prefrontal cortex following acute neuroleptic administration. Psychopharmacology 93:403–404
Christensen AV, Nielsen IM (1979) Dopaminergic supersensitivity: influence of dopamine agonists, cholinergics, anticholinergics, and drugs used for the treatment of tardive dyskinesia. Psychopharmacology 62:111–116
Christensen AV, Arnt J, Hyttel J, Larsen JJ, Svendsen O (1984) Pharmacological effects of a specific dopamine D1 antagonist SCH23390 in comparison with neuroleptics. Life Sci 34:1529–1540
Clark D, White FJ (1987) Review: D1 dopamine receptor — the search for a function: a critical evaluation of D1/D2 dopamine receptor classification and its functional implications. Synapse 1:347–388
Consolo S, Wu CF, Fusi R (1987) D-1 receptor-linked mechanism modulates cholinergic neurotransmission in rat striatum. J Pharmacol Exp Ther 242:300–305
Costall B, Hui S-CG, Naylor RJ (1978) Correlation between multi-test and single test catalepsy assessment. Neuropharmacology 17:761–764
Creese I (1983) Receptor interactions of neuroleptics. In: Coyle JT, Enna SJ (eds) Neuroleptics: neurochemical, behavioral and clinical perspectives. Raven Press, New York, pp 194–196
Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antipsychotic drugs. Science 192:481–483
Ezrin-Waters C, Seeman P (1977) Tolerance to haloperidol catalepsy. Eur J Pharmacol 41:321–327
Ezrin-Waters C, Muller P, Seeman P (1976) Catalepsy induced by morphine or haloperidol: effects of apomorphine and anti-cholinergic drugs. Can J Physiol Pharmacol 54:516–519
Fisher SK, Klinger PD, Agranoff BW (1983) Muscarinic agonist binding and phospholipid turnover in brain. J Biol Chem 258:7358–7363
Gero A (1971) Intimate study of drug action III: mechanism of molecular drug action. In: DiPalma JR (ed) Drill's pharmacology in medicine. McGraw-Hill, New York, pp 67–98
Hess EJ, Albers LJ, Hoang L, Creese I (1986) Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation. J Pharmacol Exp Ther 238:846–854
Hillegaart V, Ahlenius S, Magnusson O, Fowler CJ (1987) Repeated testing of rats markedly enhances the duration of effects induced by haloperidol on treadmill locomotion, catalepsy, and a conditioned avoidance response. Pharmacol Biochem Behav 27:159–164
Hyttel J (1983) SCH23390: the first selective dopamine D1 antagonist. Eur J Pharmacol 91:153–154
Hyttel J (1984) Functional evidence for selective dopamine D1 receptor blockade by SCH23390. Neuropharmacology 23:1395–1401
Hyttel J, Larsen JJ, Christensen AV, Arnt J (1985) Receptor binding properties of neuroleptics. In: Casey DE, Chases TN, Christensen AV, Gerlach J (eds) Dyskinesia: research and treatment. Springer, New York Berlin Heidelberg Tokyo pp 2–8
Iorio LC, Barnett A, Leitz FH, Houser VP, Korduba CA (1983) SCH23390, a potential benzazepine antipsychotic with unique interactions of dopaminergic systems. J Pharmacol Exp Ther 226:462–468
Klemm WR, Block H (1988) D-1 and D-2 receptor blockade have additive cataleptic effects in mice, but receptor effects may interact in opposite ways. Pharmacol Biochem Behav 29:223–229
Ladinsky H, Consolo S, Bianchi S, Ghezzi D, Samanin R (1978) Link between dopaminergic and cholinergic neurons in the striatum as evidenced by pharmacological and lesion studies. In: Garattini S, Pujol JF, Samanin R (eds) Interactions between putative neurotransmitters in the brain. Raven Press, New York, pp 3–21
Lloyd KG, Stadler H, Bartholini G (1973) Dopamine and acetyl-choline neurones in limbic structures: effect of neuroleptic drugs. In: Usdin E, Snyder S (eds) Frontiers in catechlamine research. Pergamon Press, New York, pp 777–779
Mailman RB, Shulz DW, Lewis MH, Staples L, Rollema H, Dehaven DL (1984) SCH23390: a selective D1 dopamine antagonist with potent D2 behavioral actions. Eur J Pharmacol 101:159–160
Meller E, Bohmaker K, Goldstein M, Friedhoff AJ (1985a) Inactivation of D1 and D2 dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by neuroleptics. J Pharmacol Exp Ther 233:656–662
Meller E, Kuga F, Friedhoff AJ, Goldstein M (1985b) Selective D2 dopamine agonists prevent catalepsy induced by SCH23390, a selective D1 antagonist. Life Sci 36:1857–1864
Morelli M, Chiara GD (1985) Catalepsy induced by SCH23390 in rats. Eur J Pharmacol 117:179–185
Munkvad I, Pakkenberg H, Randrup A (1968) Aminergic systems in basal ganglia associated with stereotyped hyperactive behaviour and catalepsy. Brain Behav Evol 1:89–100
Olianas MC, Onali P, Neff NH, Costa E (1983) Muscarinic receptors modulate dopamine-activated adenylate cyclase of rat striatum. J Neurochem 41:1364–1369
Owen F, Crow TJ, Poulter M, Cross AJ, Longden A, Riley GJ (1978) Increased dopamine receptor sensitivity in schizophrenia. Lancet II:223–226
Saller CF, Salama AI (1986) D-1 and D-2 dopamine receptor blockade: interactive effects in vitro and in vivo. J Pharmacol Exp Ther 236:714–720
Seeman P (1981) Brain dopamine receptors. Pharmacol Rev 32:229–313
Seeman P (1985) Brain dopamine receptors in schizophrenia and tardive dyskinesia. In: Casey DE, Chases TN, Christensen AV, Gerlach J (eds) Dyskinesia: research and treatment. Springer, New York Berlin Heidelberg Tokyo, pp 2–8
Shulz DW, Staples L, Mailman RB (1985) SCH23390 causes persistent antidopaminergic effects in vivo: evidence for long term occupation of receptors. Life Sci 36:1941–1948
de Sousa Moreira LF, da Concaicao Camargo Pinheiro M, Masur J (1982) Catatonic behavior induced by haloperidol, increased by retesting and elicited without drugs in rats. Pharmacology 25:1–5
Stanley ME, Glick SD (1976) Interaction of drug effects with testing procedures in the measurement of catalepsy. Neuropharmacology 15:393–394
Stoof JC, Kebabian JW (1981) Opposing roles for D-1 and D-2 dopamine receptors for efflux of cyclic AMP from rat neostriatum. Nature 294:366–368
Stoof JC, Kebabian JW (1984) Two dopamine receptors: biochemistry, physiology and pharmacology. Life Sci 35:2281–2296
Waddington JL (1986) Behavioral correlates of the action of selective D-1 dopamine receptor antagonists: impact of SCH 23390 and SKF 83566, and functionally interactive D-1:D-2 receptor systems. Biochem Pharmacol 35:3661–3667
Wilk S, Watson E, Stanley M (1975) Differential sensitivity of two dopaminergic structures in rat brain to haloperidol and clozapine. J Pharmacol Exp Ther 195:265–270
Winer BJ (1971) Statistical principles in experimental design. McGraw-Hill, New York, pp 10–428
Zetler G (1968) Cataleptic state and hypothermia in mice, caused by central cholinergic stimulation and antagonized by anticholinergic and antidepressant drugs. Int J Neuropharmacol 7:325–335
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Undie, A.S., Friedman, E. Differences in the cataleptogenic actions of SCH23390 and selected classical neuroleptics. Psychopharmacology 96, 311–316 (1988). https://doi.org/10.1007/BF00216056
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00216056